G1 Therapeutics, Inc. (GTHX) Reports In-Line Q1 EPS, reaffirms product guidance

G1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q1 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $14.48 million versus the consensus estimate of $15.06 million.

2024 Financial Guidance

G1 today reaffirmed its full year 2024 financial guidance. The Company expects to generate between $60 million and $70 million in COSELA net revenue in 2024. G1's product revenue guidance is based on expectations for continued acceleration of sales performance of COSELA in the U.S. Additionally, the Company believes that its current cash runway is sufficient to fund its operations into the third quarter of 2025.

For earnings history and earnings-related data on G1 Therapeutics, Inc. (GTHX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79